Matinas Biopharma Hl (MTNB) 1.0000 $MTNB Matinas

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2015 at 10:20 PM

Matinas Biopharma Hl (MTNB) 1.0000 $MTNB

Matinas BioPharma to Present at the 12th Anti-Infectives Partnering and Deal Making Conference
GlobeNewswire - Tue Jul 07, 6:35AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) ("Matinas BioPharma" or the "Company"

, a clinical-stage biopharmaceutical company, today announced that it will be presenting at the 12 Anti-Infectives Partnering and Deal Making Conference being held July 9-10, 2015, in Boston, MA.

Matinas BioPharma's MAT9001 Demonstrates Superiority in Reducing Triglycerides, Lipids, Apolipoproteins and PCSK9 Levels in Head-to-Head Study With Vascepa(R)
GlobeNewswire - Mon Jun 15, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company, announced the presentation of data from a head-to-head study that showed MAT9001, a prescription-only omega-3 fatty acid-based composition under development for the treatment of hypertriglyceridemia, demonstrated superiority versus Vascepa (icosapent ethyl) in reducing lipids, triglycerides, apolipoproteins and PCSK9 levels.

Matinas BioPharma to Present at the BIO International Convention on June 18, 2015
GlobeNewswire - Wed Jun 10, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting at the BIO International Convention being held June 15-18, 2015, in Philadelphia, PA.

Matinas BioPharma Announces Acceptance of Late-Breaking Abstract on MAT9001 Comparative Study Results Versus Vascepa(R) for Poster Presentation at the National Lipid Association Scientific Sessions
GlobeNewswire - Thu Jun 04, 6:05AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting additional data from the MAT9001 head-to-head comparative pharmacokinetic and pharmacodynamic (PK/PD) study versus Vascepa (icosapent ethyl) at the National Lipid Association (NLA) Scientific Sessions being held June 11-14, 2015, in Chicago, IL.

Matinas and Amarin's Destinies are Linked as MAT9001 Outshines Vascepa
ACCESSWIRE - Wed Jun 03, 2:42PM CDT
CORAL GABLES, FL / ACCESSWIRE / June 3, 2015 / It was April 2011 and Amarin (NASDAQ: AMRN) shareholders were flying high. As data came in for the company's pivotal phase 3 trial for Vascepa, an omega-3 fatty acid drug trialed to reduce very high triglycerides in the blood, shares went from $8.75 to a high of $19.50 just over a month later. But as excitement wore off, shares had collapsed down to pre-data-release levels by December.
AZN: 66.45 (+1.90), AMRN: 2.41 (+0.02), GSK: 42.45 (+0.65)

Matinas MAT9001 Beats Vascepa In Head-To-Head Trial
Jason Napodano, CFA - at Seeking Alpha - Mon Jun 01, 1:28PM CDT

AMRN: 2.41 (+0.02)

Matinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R)
GlobeNewswire - Mon Jun 01, 7:00AM CDT
- MAT9001 demonstrates superiority versus Vascepa on bioavailability, triglyceride reduction and other lipid endpoints -

Matinas BioPharma to Present at the LD Micro Invitational on June 2, 2015
GlobeNewswire - Thu May 28, 6:05AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of targeted therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the LD Micro Invitational being held June 1-3, 2015, at the Luxe Sunset Boulevard, Los Angeles, CA.

Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
GlobeNewswire - Tue May 26, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of lipid-based prescription therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the Fourth Annual SeeThru Equity Microcap Investor Conference being held May 28, 2015, at Convene Grand Central, New York, NY.

Antifungals, an Overlooked Biotech Niche With Big Potential
ACCESSWIRE - Wed May 20, 7:37AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 20, 2015 / If a global competition were held for the planet's most sadly ironic places, the hospital would place very high, if not win outright. This is not only true from before the late 19th century when the germ theory of disease became widely accepted. Before then, the hospital - a place that is designed to heal the sick - was just about the best place on Earth to contract a life-threatening infection due to unsanitary surgical procedures. This is still sadly true today as well. Hospitals are still the largest breeding grounds for deadly superbug infections due to the very sanitation procedures meant to stop them.
CDTX: 14.43 (+0.43), RTGN: 5.06 (+1.01)

Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 9.13 (+0.49), BIIB: 388.23 (-11.06), ARWR: 6.68 (+0.07), AMGN: 154.10 (+2.79), MYL: 71.22 (+0.87), BMY: 69.27 (+1.38), CNCE: 15.71 (+0.27), CELG: 118.84 (+1.97), ATNM: 2.41 (+0.18), PFS: 19.19 (+0.20), NVIV: 14.01 (-1.01), GILD: 113.74 (+0.38), FWP: 39.47 (+1.55), GWPH: 125.86 (+5.39), IBM: 166.95 (+3.10), BAX: 37.61 (+0.59), AZN: 66.45 (+1.90), TEVA: 61.38 (-0.75)

Matinas' Pipeline Is Ready To Shine
Jason Napodano, CFA - Seeking Alpha - Thu Apr 16, 2:26PM CDT
By Jason Napodano, CFA On January 30, 2015, Matinas announced the establishment of a lipid-based, anti-infective platform with the acquisition of Aquarius BioTechnologies, Inc. This was the Bioral™ technology previously owned by BioDelivery...

Matinas BioPharma Completes Private Placement of $10 Million
GlobeNewswire - Fri Apr 10, 11:20AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of infectious diseases and cardiovascular and metabolic conditions, today announced that its President and Chief Executive Officer, Roelof Rongen, will be presenting on Monday, April 13, 2015, at 8:30 a.m. Pacific Daylight Time, at the 2 Annual Growth Capital Expo being held April 12-14, 2015, at Caesars Palace in Las Vegas, Nevada.

Apparent Connections To A Convicted Stock Promoter: Another Chapter In The Organovo Saga
Alpha Exposure - Seeking Alpha - Wed Apr 01, 12:16PM CDT
Much has been written about Organovo (NYSEMKT: ONVO ) and its shortcomings. Richard Pearson showed that Organovo's 3D liver tissue is not unique, that competitors are more advanced than ONVO, and that the market opportunity for liver assays is...
ONVO: 3.82 (+0.26)

Matinas BioPharma Completes Enrollment in First Human Trial of MAT9001
GlobeNewswire - Mon Mar 30, 7:05AM CDT
- Study Steering Committee Recommends Early Completion of Enrollment Due to Adequate Power in Study to Demonstrate Study Endpoints -

Matinas BioPharma to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
GlobeNewswire - Thu Feb 05, 7:07AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"

(OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions and the treatment of infectious diseases, announced today that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York.

Matinas Biopharma Acquires Aquarius Biotechnologies
Jason Napodano, CFA - at Seeking Alpha - Wed Feb 04, 6:09PM CST

Matinas BioPharma Establishes Lipid-Based, Anti-Infective Platform, With Acquisition of Aquarius BioTechnologies Inc.
GlobeNewswire - Fri Jan 30, 7:25AM CST
- Novel lipid-crystal nano-particle cochleate formulation delivery platform with opportunity for broad use in anti-infectives featuring targeted delivery and multi-organ protection -

Matinas BioPharma Holdings, Inc. - Increasing Evidence That Elevated Triglycerides Cause Cardiovascular Events
ACCESSWIRE - Thu Jan 08, 12:18PM CST
New York, NY / ACCESSWIRE / January 8, 2015 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a new blog post on The Chairman's Blog, written by the Company's Co-Founder and CEO, Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PACS Group Faces Legal Scrutiny: What to Watch

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

AI and Storytelling Make Waves in Science Education

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...